MannKind Corporation - Common Stock (NQ:MNKD)

3.420 +0.110 (+3.32%)

Streaming Delayed Price Updated: 12:17 PM EDT, May 22, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about MannKind Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

MannKind Corporation Reports 2022 Fourth Quarter and Full Year Financial Results

February 23, 2023

Conference Call to Begin Today at 5:00 p.m. (ET)

From MannKind

Via GlobeNewswire

MannKind Earnings Preview ↗

February 22, 2023

Via Benzinga

MannKind to Give Oral Presentation on Meal Challenge Results From the Afrezza® With Basal Combination (ABC Study) at 16th Annual ATTD Conference

February 22, 2023

From MannKind

Via GlobeNewswire

MannKind Corporation to Hold 2022 Fourth Quarter and Full Year Financial Results Conference Call on February 23, 2023

February 16, 2023

From MannKind

Via GlobeNewswire

MannKind's Return On Capital Employed Overview ↗

December 05, 2022

Via Benzinga

MannKind Corporation (MNKD) Q3 2022 Earnings Call Transcript ↗

November 08, 2022

MNKD earnings call for the period ending September 30, 2022.

Via The Motley Fool

MannKind: Q2 Earnings Insights ↗

August 09, 2022

MannKind (NASDAQ:MNKD) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Earnings Scheduled For February 23, 2023 ↗

February 23, 2023

Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.

Via Benzinga

Mannkind Corporation to Participate in the SVB Securities Global Biopharma Conference

February 10, 2023

From MannKind

Via GlobeNewswire

MannKind Corporation to Participate in the Lytham Partners Investor Select Conference

January 24, 2023

From MannKind

Via GlobeNewswire

MannKind’s Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease

January 23, 2023

From MannKind

Via GlobeNewswire

3 Biotech Stocks Under $15 Worth a Second Look in 2023 ↗

January 18, 2023

All three stocks have promising therapies that could drive revenue in the coming years.

Via The Motley Fool

MannKind Corporation to Present at 2023 Annual J.P. Morgan Healthcare Conference

January 05, 2023

From MannKind

Via GlobeNewswire

MannKind to Present Two Posters at 22nd Annual Diabetes Technology Meeting

November 10, 2022

From MannKind

Via GlobeNewswire

MannKind To Rally 57%? Here Are 5 Other Price Target Changes For Wednesday ↗

November 09, 2022

Via Benzinga

Tyson Foods To $61? Plus Needham Slashes PT On This Stock By 33% ↗

November 09, 2022

B of A Securities cut the price target on Tyson Foods, Inc. (NYSE: TSN) from $73 to $61. Tyson Foods shares fell 1.9% to $66.44 in pre-market trading.

Via Benzinga

MannKind Corporation Reports 2022 Third Quarter Financial Results

November 08, 2022

Conference Call to Begin Today at 9:00 a.m. (ET)

From MannKind

Via GlobeNewswire

Earnings Preview: MannKind ↗

November 07, 2022

MannKind (NASDAQ:MNKD) is set to give its latest quarterly earnings report on Tuesday, 2022-11-08. Here's what investors need to know before the announcement. Analysts estimate that MannKind will...

Via Benzinga

MannKind Corporation to Hold 2022 Third Quarter Financial Results Conference Call on November 8, 2022

November 01, 2022

From MannKind

Via GlobeNewswire

7 Penny Sleeper Stocks to Buy Before Wall Street Wakes Up ↗

September 29, 2022

While these market ideas are risky, they offer enough relevance to be intriguing.

Via InvestorPlace

7 Penny Stocks That Actually Have a Buy Rating ↗

September 19, 2022

Penny stocks are always a risky proposition. However, investors can still find penny stocks with buy ratings right now.

Via InvestorPlace

MannKind Shares Fall After Completing Initial Stage Lung Disease Study ↗

September 06, 2022

MannKind Corporation (NASDAQ: MNKD) has successfully completed a Phase 1 study of clofazimine inhalation suspension (MNKD 101), an inhalation treatment option for nontuberculous mycobacterial (NTM)...

Via Benzinga

Earnings Outlook For MannKind ↗

August 08, 2022

MannKind (NASDAQ:MNKD) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement. Analysts estimate that MannKind will...

Via Benzinga

Jim Cramer Recommends Selling This Stock: 'No One Ever Likes Me To Say Anything Bad' About This Company ↗

August 04, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Canoo Inc. (NASDAQ: GOEV) is losing money. "We’re done with those stocks that just lose money," he added.

Via Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation ↗

May 17, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

7 Biotech Stocks With Key Catalysts for May ↗

May 11, 2022

The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns.

Via InvestorPlace

MannKind Earnings Preview ↗

May 04, 2022

MannKind (NASDAQ:MNKD) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that MannKind will...

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

March 17, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

3 Market ETF Stocks to Buy This Week on Fed Jitters ↗

March 14, 2022

The bears have two major tailwinds and the Fed is one. Here are 3 ETF stocks to buy into a potential relief rally after the event blows over.

Via InvestorPlace

68 Biggest Movers From Yesterday ↗

March 03, 2022

Gainers ECMOHO Limited (NASDAQ: MOHO) climbed 56.7% to close at $0.3650 on Wednesday after jumping 10% on Tuesday. Imperial Petroleum Inc. (NASDAQ: IMPP) shares jumped 39.2% to...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.